Three oral presentations underscore Novocure’s commitment to further
understanding the physical application of Tumor Treating Fields to
enhance efficacy
ST. HELIER, Jersey--(BUSINESS WIRE)--
Novocure (NASDAQ: NVCR) announced today that three oral presentations on
Tumor Treating Fields (TTFields) will be given at the 39th
Annual International Conference of the IEEE Engineering in Medicine and
Biology Society (EMBS) on July 11 through July 15 in Jeju Island, Korea.
The presentations include Novocure’s latest data on evaluating induced
electric fields in human head models, evaluating electric field
distribution in patients treated using human models, and determining the
dielectric properties of human skin.
“Novocure’s latest research on the delivery of TTFields underscores our
commitment to further understanding the physical application of our
profoundly different cancer treatment,” said Dr. Eilon Kirson,
Novocure’s Chief Science Officer and Head of Research and Development.
“Our therapy bridges physics and biology, and presents us with the
opportunity to make clinical advancements and to advance the engineering
of our TTFields delivery systems. We are pleased to share these data
with the biomedical engineering community.”
EMBS is the world’s largest international society of biomedical
engineers with 12,000 members in 97 countries. The organization provides
its members with resources that are shaping one of the fastest growing
fields in science.
The following oral presentations will be given on Thursday, July 13:
Application of Realistic Human Head Models for Evaluating Induced
Electric Fields: A Discussion on Feasible Model Creation, Influential
Model Assumptions, and Necessary Degree of Complexity (I); Cornelia
Wenger, Pedro Cavaleiro Miranda; Paper ThAT12.2
Evaluating Electric Field Distribution in the Heads of Patients Treated
with Tumor Treating Fields Using Realistic Human Models Created with a
Deformable Template (I); Noa Urman, Hadas Hershkovich, Uri Weinberg,
Cornelia Wenger, Eilon Kirson and Ze'ev Bomzon; Paper ThAT12.5
Determining the Dielectric Properties of Human Skin in the Frequency
Range of 0.1 to 1 MHZ, and Implications to the Modelling of Tumor
Treating Fields (I); Hadas Sara Hershkovich, Noa Urman, Ariel Naveh,
Ofir Yesharim, Yoram Wassermann, Eilon Kirson and Ze'ev Bomzon; Paper
ThCT12.3
About Novocure
Novocure is an oncology company developing a profoundly different cancer
treatment utilizing a proprietary therapy called TTFields, the use of
electric fields tuned to specific frequencies to disrupt solid tumor
cancer cell division. Novocure’s commercialized product, Optune, is
approved for the treatment of adult patients with glioblastoma. Novocure
has ongoing or completed clinical trials investigating TTFields in brain
metastases, non-small cell lung cancer, pancreatic cancer, ovarian
cancer and mesothelioma.
Headquartered in Jersey, Novocure has U.S. operations in Portsmouth, New
Hampshire, Malvern, Pennsylvania, and New York City. Additionally, the
company has offices in Germany, Switzerland and Japan, and Israel. For
additional information about the company, please visit www.novocure.com
or follow us at www.twitter.com/novocure.
Forward-Looking Statements
In addition to historical facts or statements of current condition, this
press release may contain forward-looking statements. Forward-looking
statements provide Novocure’s current expectations or forecasts of
future events. These may include statements regarding anticipated
scientific progress on its research programs, development of potential
products, interpretation of clinical results, prospects for regulatory
approval, manufacturing development and capabilities, market prospects
for its products, and other statements regarding matters that are not
historical facts. You may identify some of these forward-looking
statements by the use of words in the statements such as “anticipate,”
“estimate,” “expect,” “project,” “intend,” “plan,” “believe” or other
words and terms of similar meaning. Novocure’s performance and financial
results could differ materially from those reflected in these
forward-looking statements due to general financial, economic,
regulatory and political conditions as well as more specific risks and
uncertainties facing Novocure such as those set forth in its Annual
Report on Form 10-K filed on February 23, 2017, with the U.S. Securities
and Exchange Commission. Given these risks and uncertainties, any or all
of these forward-looking statements may prove to be incorrect.
Therefore, you should not rely on any such factors or forward-looking
statements. Furthermore, Novocure does not intend to update publicly any
forward-looking statement, except as required by law. Any
forward-looking statements herein speak only as of the date hereof. The
Private Securities Litigation Reform Act of 1995 permits this discussion.
View source version on businesswire.com: http://www.businesswire.com/news/home/20170711005314/en/
Source: Novocure